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Leishmaniasis, Chagas Disease and Dengue are examples
of neglected infectious disease that, together with
Malaria, are responsible for over 1 million deaths each
year. In all cases, new treatments are badly needed.
Malaria treatment, although available, is becoming pro-
blematic due to worldwide spread of parasite resistance
to drugs. For Leishmaniasis, drugs are often ineffective
due to the pathogens’ resistance, and in some cases the
drugs themselves are potentially deadly for patients. For
Chagas, available treatment is often ineffective past the
acute phase of the disease, and for Dengue there is no
current treatment available at all.
IP-Korea develops Phenomic Screen™, image-based
high-content/high-throughput screening assays to find
new drugs against Leishmaniasis. Using a whole-cell-
based approach, we designed assays that allow selection
of compounds that have potent activity against patho-
gens and are not toxic for the human cells. These cellu-
lar assays were adapted to high-throughput for
automated image acquisition. Using this technology we
have screened 200,000 drugs that impair the growth of
the most deadly species causing visceral Leishmaniasis,
inside their natural host cell, the human macrophages.
We have also developed a phenotypic screen for Cha-
gas disease and screened 150,000 compounds, in colla-
boration with Pfizer and the Drugs for Neglected
Diseases initiative (DNDi), for their ability to inhibit
Trypanosoma cruzi, the parasite causing Chagas, inside
human host cells. Also, we established visual screening
procedure to screen human genome in high content
imaging mode within 8h. Genome-wide RNAi screening
to identify human host proteins that are required in
Chagas disease infection has been finished. The identifi-
cation of these factors provides potential new targets for
anti-parasitic therapies.
Dengue is still in the early stage but is progressing
towards the development of a cell-based high-through-
put screening assay using different virus serotypes and
clinical isolates.
For malaria, we are developing HCS/HTS assays that
target the invasion of human red blood cells by the
deadliest of all malaria parasites, P. falciparum. We have
screened 80,000 compounds for their antimalarial activ-
ity, and the selected hits will be re-tested for their ability
to interfere with the invasion pathway using an image
based high-content assay. In parallel, we are developing
a phenotypic assay to screen for drugs that interfere
with P. falciparum infected red blood cells cytoadhesion,
one the main pathogenic mechanism of this parasite.
Published: 10 January 2011
doi:10.1186/1753-6561-5-S1-L6
Cite this article as: Nehrbass: Phenomic technologies in drug discovery
of neglected diseases. BMC Proceedings 2011 5(Suppl 1):L6.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit Institut Pasteur-Korea, Gyeonggi-do, Korea
Nehrbass BMC Proceedings 2011, 5(Suppl 1):L6
http://www.biomedcentral.com/1753-6561/5/S1/L6
© 2011 Nehrbass; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.